Literature DB >> 2372888

Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies.

P Nihoyannopoulos1, P M Gomez, J Joshi, S Loizou, M J Walport, C M Oakley.   

Abstract

Two-dimensional echocardiographic studies were prospectively performed in 93 patients with systemic lupus erythematosus (SLE) to discover the incidence and spectrum of cardiac abnormalities and to relate these findings to the presence of high levels of anticardiolipin antibodies. Assessment of the intracardiac anatomy was also performed in an additional 12 patients who had increased anticardiolipin antibody levels but did not have SLE. Fifty patients (54%) with SLE had cardiac abnormalities, and 43 patients (46%) had normal hearts. Three categories of cardiac abnormalities were identified--valvular lesions, ranging from vegetations to valvular thickening, were found in 28%, pericardial effusion or thickening was found in 20%, and regional or global left ventricular dysfunction was found in 5%. High levels of anticardiolipin antibodies were detected in 50 patients (54%) with SLE. Of those, only 11 (22%) had an entirely normal heart, whereas the remaining 39 (78%) had at least one cardiac abnormality (valvular lesions in 20, pericardial effusion in 15, and myocardial dysfunction in five patients). In patients with SLE, the presence of abnormal intracardiac anatomy was strongly associated with increased levels of anticardiolipin antibodies (p less than 0.0001). The overall sensitivity and specificity of high levels of anticardiolipin antibodies in the prediction of cardiac abnormalities was 78% and 74%, respectively, with a positive predictive accuracy of 78% and a negative predictive accuracy of 74%. Eight of the 12 patients (67%) who had increased anticardiolipin antibodies but whose disease did not fulfill the American Rheumatism Association classification criteria for SLE had cardiac abnormalities similar to those in patients with SLE compared with only four (33%) who had normal hearts (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2372888     DOI: 10.1161/01.cir.82.2.369

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

Review 1.  Cardiac valvulopathy in the antiphospholipid syndrome.

Authors:  Shaul Lev; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

Review 2.  Antiphospholipid antibodies and cardiovascular disease.

Authors:  H L Beynon; M J Walport
Journal:  Br Heart J       Date:  1992-04

Review 3.  The antiphospholipid syndrome: a syndrome in evolution.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

4.  Heart valve disease in systemic lupus erythematosus. Role of antiphospholipid antibodies.

Authors:  O Meyer; M Golstein; P Nicaise; C Labarre; M F Kahn
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

5.  Diastolic impairment in asymptomatic systemic lupus erythematosus patients.

Authors:  E Astorri; P Fiorina; G A Contini; D Albertini; E Ridolo; P Dall'Aglio
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

6.  Double-valve Libman-Sacks endocarditis causing ventricular fibrillation cardiac arrest.

Authors:  Tanyanan Tanawuttiwat; Muhyaldeen Dia; Tabassum Hanif; Mihaela Mihailescu
Journal:  Tex Heart Inst J       Date:  2011

7.  Surgical treatment of nonbacterial thrombotic endocarditis presenting with stroke.

Authors:  A A Rabinstein; C Giovanelli; J G Romano; S Koch; A M Forteza; M Ricci
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

8.  Simultaneous liver resection and double cardiac valve replacement. A case report.

Authors:  F Ausania; D Hipps; D M Manas; B Haugk; J H Dark; B C Jaques
Journal:  Int J Surg Case Rep       Date:  2014-03-19

Review 9.  Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review.

Authors:  Priscila Mattos; Mittermayer B Santiago
Journal:  Clin Rheumatol       Date:  2011-01-05       Impact factor: 2.980

10.  Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies.

Authors:  Piotr Leszczyński; Ewa Straburzyńska-Migaj; Izabela Korczowska; Jan K Łacki; Stefan Mackiewicz
Journal:  Clin Rheumatol       Date:  2003-10-14       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.